SHOULDER INNOVATIONS, INC.
According to a Form 10-K filed May 13, 2026, Gilde Healthcare and related Dutch entities hold 2,212,207 shares of Shoulder Innovations, Inc. common stock, or 10.7% based on 20,738,226 shares outstanding as of May 6, 2026. The filing also reports open-market sales in late July to early August 2026, including 99,812 shares sold Aug. 4 at a weighted average $22.77.
Gilde Healthcare Holding B.V. sold 9,433 indirectly-held shares of SHOULDER INNOVATIONS, INC. (SI) at an average of $22.63 ($22.60–$22.64, $0.21M total) across 2 trades over 2026-08-05 to 2026-08-06.
Shoulder Innovations (NYSE: SI) reported Q2 2026 net revenue of $17.2 million, up 56% year over year, with gross margin of 78.3%. Full-year 2026 net revenue guidance was raised to $67 million to $69 million. Cash and marketable securities totaled $99.0 million as of June 30, 2026.
Over the past 7 days, alphai's AI scored 4 news stories mentioning SI (SHOULDER INNOVATIONS, INC.). Coverage has skewed bullish: 3 bullish, 1 neutral, and 0 bearish.
Recent SI coverage spans mergers & acquisitions, insider activity and earnings.
In the last 30 days, SI insiders filed 6 SEC Form 4 transactions — no purchases and 6 sales ($3.8M). The most active reporter was Gilde Healthcare Holding B.V. with 6 filings.
A major-holder stake update with disclosed open-market sales can shift perceived control and near-term supply overhang, but it is not an operating or fundamental change.
This is an insider (10% owner) indirect sale with no 10b5-1 plan disclosed, which can modestly affect near-term sentiment but is not a fundamental catalyst.
Guidance raise plus strong Q2 growth supports a near-term positive re-rating, but losses and rising opex keep volatility elevated.
Deal announcement is a strategic expansion of Siemens Digital Industries Software’s EDA stack, potentially improving competitive positioning in AI-assisted SoC feasibility.
Guidance raise plus strong implant volume and gross margin expansion are likely to support near-term sentiment, but losses and rising opex remain key risk factors.
alphai scores every news story that mentions SI with an AI model for sentiment and relevance, and aggregates insider trades from SHOULDER INNOVATIONS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
According to a Form 10-K filed May 13, 2026, Gilde Healthcare and related Dutch entities hold 2,212,207 shares of Shoulder Innovations, Inc. common stock, or 10.7% based on 20,738,226 shares outstanding as of May 6, 2026. The filing also reports open-market sales in late July to early August 2026, including 99,812 shares sold Aug. 4 at a weighted average $22.77.
2 min readGilde Healthcare Holding B.V. sold 9,433 indirectly-held shares of SHOULDER INNOVATIONS, INC. (SI) at an average of $22.63 ($22.60–$22.64, $0.21M total) across 2 trades over 2026-08-05 to 2026-08-06.
2 min readShoulder Innovations (NYSE: SI) reported Q2 2026 net revenue of $17.2 million, up 56% year over year, with gross margin of 78.3%. Full-year 2026 net revenue guidance was raised to $67 million to $69 million. Cash and marketable securities totaled $99.0 million as of June 30, 2026.
4 min readSiemens said it signed an agreement to acquire privately held US EDA software firm Precision Innovations. Siemens said the deal will add AI-powered chip planning and early design exploration using the OpenROAD framework to help semiconductor teams optimize power, performance and area, reduce iterations, and speed SoC feasibility analysis and time to market.
2 min readSHOULDER INNOVATIONS, INC. (SI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex-991earningsreleaseq22026.htm EX-99.1 Document Exhibit 99.1 Shoulder Innovations Reports Second Quarter 2026 Financial Results and Raises Full Year Outlook Generates First Half 2026 Revenue Growth of 60% Grand Rapids, MI – August 6, 2026 – Shoulder Innovations, Inc. (
6 min readGilde Healthcare Holding B.V. sold 48,279 indirectly-held shares of SHOULDER INNOVATIONS, INC. (SI) at an average of $23.10 ($22.73–$23.36, $1.12M total) across 2 trades over 2026-07-30 to 2026-07-31.
2 min readBiotech shares hit 52-week highs on July 28, 2026. Incyte (INCY) rose over 9% to $132.58 after Q2 revenue of $1.67B, up 38% year over year, and raised full-year net sales guidance to $5.13B-$5.26B. Pulse Biosciences (PLSE) gained over 8% to $36.29. Other climbers included Shoulder Innovations (SI), Bioventus (BVS), and LB Pharmaceuticals (LBRX).
4 min readSiemens said it has acquired Precision Innovations, a privately held San Diego EDA software firm founded seven years ago. Precision Innovations builds EDA tools on the open-source OpenROAD framework for semiconductor design feasibility and early exploration. Siemens said the deal will expand its EDA portfolio with AI-driven chip planning and design exploration to speed time to silicon.
3 min readSiemens said it agreed to acquire privately held Precision Innovations Inc., an electronic design automation firm. Siemens will add Precision’s AI-powered chip planning tools to its EDA portfolio to help semiconductor teams evaluate design tradeoffs earlier in system-on-a-chip development, aiming to improve power, performance and area outcomes and speed time to production.
3 min readBiotech gainers highlighted Q32 Bio (QTTB), up 90.7% to $21.38 after positive Phase 2 SIGNAL-AA results for bempikibart in alopecia areata, and it launched a $200M underwritten stock offering. Agenus (AGEN) rose 82.7% to $6.12 on a planned ~$85M private placement for BOT+BAL Phase 3 ROBBIN1. Other movers: ACTU, GALT, AMWL, SI.
7 min read
